<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738088</url>
  </required_header>
  <id_info>
    <org_study_id>2007DM02</org_study_id>
    <secondary_id>EudraCT 2007-000594-29</secondary_id>
    <nct_id>NCT00738088</nct_id>
  </id_info>
  <brief_title>Variation in Sulphonylurea Response in Type 2 Diabetes</brief_title>
  <official_title>The Use of Glycaemic Response to Sulphonylureas as a Tool to Investigate Type 2 Diabetes Pathophysiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Tayside</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that people who respond well to sulphonylureas have a different&#xD;
      underlying cause for their diabetes than people who respond poorly to this medication. We are&#xD;
      using two approaches to study this. In one approach we look at people who have previously&#xD;
      responded well or poorly, confirm this by rechallenging them with a sulphonylurea drug, and&#xD;
      then looking at how well they produce insulin in response to glucose and an intravenous&#xD;
      sulphonylurea called tolbutamide. The second approach identifies people with a certain&#xD;
      genetic predisposition to diabetes (due to changes in the TCF7L2 gene) and then looks at how&#xD;
      well they respond to sulphonylurea medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following Regulator inspection in 2009, study terminated as inadequate approvals were in place&#xD;
  </why_stopped>
  <start_date type="Actual">June 2007</start_date>
  <completion_date type="Actual">March 3, 2011</completion_date>
  <primary_completion_date type="Actual">March 3, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c reduction</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin secretory response to glucose and tolbutamide</measure>
    <time_frame>acute</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gliclazide</intervention_name>
    <description>Gliclazide 80mg bd for 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Diamicron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Age &gt;35 and &lt; 70&#xD;
&#xD;
          -  Age of diabetes diagnosis &gt;35 and &lt;70&#xD;
&#xD;
          -  White European&#xD;
&#xD;
          -  Pre-SU HbA1c &lt;=10%&#xD;
&#xD;
          -  HbA1c (on treatment) &lt;= 9%&#xD;
&#xD;
          -  No myocardial infarction or Acute coronary syndrome in previous year&#xD;
&#xD;
          -  No stroke or transient ischaemic attack in previous year&#xD;
&#xD;
          -  No or stable (background) retinopathy (no unscheduled laser treatment in the last 6&#xD;
             months)&#xD;
&#xD;
          -  eGFR &gt; 60mls/min&#xD;
&#xD;
          -  No Proteinuria &gt;30mg/dl on multistix 10SG&#xD;
&#xD;
          -  No active foot ulceration or infection&#xD;
&#xD;
          -  Liver ALT â‰¤ twice the upper limit of the reference range&#xD;
&#xD;
          -  Contactable by telephone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  HbA1c &gt;10% prior to commencing SU&#xD;
&#xD;
          -  HbA1c&gt;9% on SU treatment&#xD;
&#xD;
          -  Recent MI or Stroke within last 12 months&#xD;
&#xD;
          -  Pre-proliferative or proliferative retinopathy&#xD;
&#xD;
          -  eGFR&lt;60 ml/min&#xD;
&#xD;
          -  Proteinuria &gt;30mg/dl on multistix 10SG&#xD;
&#xD;
          -  Active foot ulceration or infection&#xD;
&#xD;
          -  Liver ALT &gt; twice the upper limit of the reference range&#xD;
&#xD;
          -  Female planning to conceive within the study period&#xD;
&#xD;
          -  Any other significant medical reason for exclusion as determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewan R Pearson</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Tayside</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NHS Tayside</investigator_affiliation>
    <investigator_full_name>Ewan Pearson</investigator_full_name>
    <investigator_title>Professor of Diabetic Medicine</investigator_title>
  </responsible_party>
  <keyword>Sulphonylurea</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

